Take a trial of UK to unlock this pageFind out more

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 30th Jun 2010 2011 2012 2013 2014 2015 2016E 2017E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Last ex-div: 5th Nov, paid: 3rd Dec more... Dividends
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p +17.7%

FINANCIAL BRIEF: For the fiscal year ended 30 June 2015, Regenersis PLC revenues increased 3% to L202.6M. Net income increased 82% to L5.4M. Revenues reflect Depot Solutions segment increase of 2% to L154.3M, Software and advanced solutions segment increase of 4% to L48.3M, Other Foreign segment increase of 54% to L55.3M, Poland segment increase of 14% to L51.2M, Germany segment increase of 15% to L31.5M. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 30th Jun '15) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
30th Jun 2016
30th Jun 2017

Price Target: 2.51
(+30.21% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
5 brokers Broker Consensus Trend
Broker Recommendations for Regenersis
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 0 2 1

Named Brokers and Analysts
Arden Partners Benjamin Thefaut , Panmure Gordon Adrian Kearsey , Peel Hunt Charles Hall , Edison Investment Research Dan Ridsdale , Equity Development Paul Hill , Cenkos Securities Martin O'Sullivan ,

Profile Summary

Regenersis Plc is a provider of diagnostics, repair and data erasure services to the consumer electronics industry. The Company offers a full cycle refurbishment service, device diagnostics, protection and repair, and onward disposition. The Company's operating divisions include Depot Solutions, Advanced Solutions and Software. The Depot Solutions division provides the Company's geographic infrastructure and repair service, and includes the operations in Germany, Poland, Romania, Turkey, South Africa, Spain, Argentina, Mexico and Czech Republic. The Software and Advanced Solutions division comprises of two segments. The Advanced Solutions segment includes the set top box activities in Glenrothes, the set top box diagnostics business, including the In Field Tester business and other remote diagnostics capabilities, and the Digital Care Insurance. The Software segment includes the Blancco business and the Xcaliber smartphone diagnostic business, which is focused on product development.

Directors: Matthew Peacock (CHM) 51, Jog Dhody (CFO) , Patrick Clawson (CEX) 49, Ian Powell (CEX) 52, Thomas Russell (EDR) 35, Thomas Skelton (NED) 54, Robert Woodward (NED) 53, Frank Blin (NID) 60,

No. of Employees: 4,249 No. of Shareholders: n/a

Last Annual June 30th, 2015
Last Interim June 30th, 2015
Incorporated April 27, 2004
Public Since March 31, 2005
Shares in Issue 79,022,599
Free Float 75.4m (95.4%)
Sector Industrials
Industry Professional & Commercial Services
Index FTSE Intl-aim All Share ,
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?

RGS Share Price Performance RGSQuote
-1.5  -0.8%
Traded 2:12pm · Minimum 15 min delayed · NMS: 5.00k

Latest RGS News Announcements (delayed)

Upcoming RGS Events
Tuesday 8th March, 2016
Half Year 2016 Regenersis PLC Earnings Release

Recent ↓
Thursday 5th November, 2015
Dividend For RGS.L
Thursday 14th May, 2015
Dividend For RGS.L
Tuesday 17th March, 2015
Half Year 2015 Regenersis PLC Earnings Presentation (London)
Tuesday 17th March, 2015
Half Year 2015 Regenersis PLC Earnings Release
Wednesday 14th January, 2015
Regenersis PLC Trading Statement Release
Wednesday 26th November, 2014
Regenersis PLC Ordinary Shareholders Meeting
Wednesday 26th November, 2014
Regenersis PLC Annual Shareholders Meeting
Thursday 6th November, 2014
Dividend For RGS.L
Tuesday 23rd September, 2014
Full Year 2014 Regenersis PLC Earnings Presentation
Tuesday 23rd September, 2014
Full Year 2014 Regenersis PLC Earnings Release
Tuesday 15th July, 2014
Regenersis PLC Trading Statement Release
Wednesday 14th May, 2014
Dividend For RGS.L

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2016.

Should you buy RGS

Access RGS Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis